EP Patent

EP2455080A1 — S1P1 receptor agonists for use in the treatment of multiple sclerosis

Assigned to Almirall SA · Expires 2012-05-23 · 14y expired

What this patent protects

a S1 P1 receptor agonist of formula (I), or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer or deuterated derivate thereof, alone or combined with IFNβ, for use in the treatment of multiple sclerosis disease.

USPTO Abstract

a S1 P1 receptor agonist of formula (I), or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer or deuterated derivate thereof, alone or combined with IFNβ, for use in the treatment of multiple sclerosis disease.

Drugs covered by this patent

Patent Metadata

Patent number: EP2455080A1
Jurisdiction: EP
Classification: —
Expires: 2012-05-23
Drug substance claim: No
Drug product claim: No
Assignee: Almirall SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.